Literature DB >> 3838875

Effect of hyperthyroidism and its treatment on bone mineral content.

S H Toh, B C Claunch, P H Brown.   

Abstract

Patients with hyperthyroidism may develop osteopenia associated with fractures; however, there has been no general agreement on the incidence of osteopenia in hyperthyroidism or the recovery of the mineral loss after treatment of hyperthyroidism. We conducted a longitudinal prospective study on the effect of hyperthyroidism and its treatment on bone mineral content (BMC) using photon absorptiometry. We observed that both young and older hyperthyroid patients showed a significantly decreased baseline BMC compared with age- and sex-matched controls. We also observed a slight recovery of BMC in hyperthyroid patients at the two-year interval after a euthyroid state had been achieved. However, the BMC was still much lower than that of controls, and we did not find any significant restoration of BMC following "cure" of hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838875

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  19 in total

Review 1.  Bone and thyroid hormones.

Authors:  F Tremollieres; J M Pouilles; J P Louvet; C Ribot
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

2.  Effects of cyclosporins and transforming growth factor beta 1 on thyroid hormone action in cultured fetal rat limb bones.

Authors:  P Lakatos; P H Stern
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

3.  Spontaneous release of interleukin 1 beta from human blood monocytes in thyrotoxic osteodystrophy.

Authors:  D Bisbocci; V Gallo; P Damiano; L Sidoli; R Cantoni; G Aimo; G Priolo; R Pagni; L Chiandussi
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

4.  Bone mineralization and calciotropic hormones in children with hyperthyroidism. Effects of methimazole therapy.

Authors:  G Saggese; S Bertelloni; G I Baroncelli
Journal:  J Endocrinol Invest       Date:  1990 Jul-Aug       Impact factor: 4.256

5.  Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.

Authors:  Takafumi Majima; Yasato Komatsu; Kentaro Doi; Chieko Takagi; Michika Shigemoto; Atsushi Fukao; Takeshi Morimoto; Jerry Corners; Kazuwa Nakao
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

6.  Risks Associated with Treating Hypothyroidism: Potential hazards of L-thyroxine therapy.

Authors:  H C Gerstein
Journal:  Can Fam Physician       Date:  1992-06       Impact factor: 3.275

Review 7.  Rheumatic manifestations of pituitary tumors.

Authors:  S Stavrou; D L Kleinberg
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

8.  A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.

Authors:  M T McDermott; J J Perloff; G S Kidd
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

9.  The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.

Authors:  M Yamamoto; A Markatos; J G Seedor; P Masarachia; M Gentile; G A Rodan; R Balena
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

10.  Effect of therapy for thyroid dysfunction on musculoskeletal symptoms.

Authors:  M Kloppenburg; B A Dijkmans; J J Rasker
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.